

## PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES

May 10, 2016

The meeting was called to order at approximately 1:44 p.m. on Tuesday May 10, 2016.

Committee members present: Anita Steinbergh, D.O.; Curtis Gingrich, M.D.; James Fry, PA-C; Irina Petty, PA-C; Megan Marchal, Pharm D; Megan Keller, Pharm D; Robert Zaayer, PA-C; and Donald Roberts

Staff members present: Sallie Debolt, and Cathy Hacker

Guests: Beth Adamson, OAPA, Scott Cackler, PA-C, President OAPA; Greg Lestini, and Marjorie Lano representatives from Bricker and Eckler.

### **I. Review of the April 12, 2016 minutes:**

Dr. Steinbergh moved to approve the minutes from the April 12, 2016 meeting. Dr. Gingrich seconded the motion. All members voted aye. The motion carried.

### **II. Review Formulary**

The committee discussed new medications to the market from 2015 Facts and comparison. It was noted that the following medications were already part of the formulary and belong in the following categories:

Avycaz an antibacterial is in the CTP may prescribe category.

Genvoya an antiviral is in the PI category

Cresamba an antifungal is in the CTP may prescribe category

The following antineoplastics are all in the CTP may not prescribe category:  
Ibrance; Lenvima; Farydak; Unituxin; Odomzo; Lonsurf; Yondelis; Cotellic; Tagrisso; Darzalex; Ninlaro; Portazza; Empliciti; and Alecensa.

Savaysa an anticoagulant is in the PI category

The following antipsychotics are all in the PI category:  
Vraylar; Aristada and Rexulti

Strensiq a bone mineralization was added to the formulary as PI.

Viberzi a GI Agent is in the formulary under the CTP may prescribe category.

Natpara a parathyroid hormone is in the PI category

Tresiba a long acting injectable insulin is in the CTP may prescribe category.

Daklinza was added to the formulary under the Anti Hep C heading in the CTP may prescribe category.

Kengreal was added to a new category of non-thienopyridine in the PI category.

Praxbind was added to a new category of anticoagulant reversal in the PI category.

Corlanor was added to the pulmonary arterial hypertension in the PI category due to contraindications.

Entresto was added to pulmonary arterial hypertension in the CTP may prescribe category.

Upravi was added to pulmonary arterial hypertension in the PI category.

Orkambi was added to monoclonal antibody section in the PI category.

Nucala was added to monoclonal antibody section in the PI category

Ms. Keller move to approve these changes to the formulary. Ms. Marchal seconded the motion. All members voted aye. The motion carried.

Dr. Gingrich moved to table the remaining medications on the list to review at the next meeting. Ms. Petty seconded the motion. All members voted aye. The motion carried.

Dr. Steinbergh moved to table the request from Dr. Schneider for a medication review until the next meeting. Ms. Keller seconded the motion. All members voted aye. The motion carried.

### ***III. Rules review***

#### **RULE DISCUSSION:**

Ms. Debolt requested that 4730-1-01 be approved for filing with CSI as drafted.

Dr. Steinbergh moved to approve these actions. Dr. Gingrich seconded the motion. All members voted aye. The motion carried.

Ms. Debolt stated that rule 4730-1-05 received lots of comments about the proposed QA requirements stating that they were onerous to the practitioners. It was noted that the Peer review that is done in the Hospitals is not available to the Board for review as QA.

Mr. Fry recommended tabling the discussion of this rule until there is more information available from OHP and other interested parties regarding this issue. Dr. Steinbergh seconded the motion. All members voted aye. The motion carried.

Ms. Debolt stated that rule 4730-2-02 needs to be rescinded as it is no longer needed.

Ms. Debolt stated that rule 4730-2-10 needs to be rescinded as the changes to the current rule are too numerous and a new rule be written regarding PA's using the OARRS system.

Dr. Steinbergh moved to approve rescinding these rules and filing with CSI. Dr. Gingrich seconded the motion. All members voted aye. The motion carried.

Ms. Debolt stated that rules 4730-2-01 and 4730-2-07 have been amended to reflect the current terminology of the statute.

Ms. Debolt requested approval of rescinding rules 4730-2-08 and 4730-2-09 as they unnecessarily repeat what is in the current law.

Dr. Steinbergh moved to approve the amendments to rules 4730-2-01 and 4730-2-07 and the rescission of rules 4730-2-08 and 4730-2-09 as unnecessary. Dr. Gingrich seconded the motion. All members voted aye. The motion carried.

Ms. Debolt request that rules 4730-2-04 and 4730-2-05 be rescinded and new rules be written to address the 500 hours of onsite supervision during the first year of prescribing. Mr. Zaayer noted that there is legislation pending that will allow PA's to obtain prescribing in Ohio that were previously not eligible and recommended that we table this rule for further discussion on how these people fall into the first 500 hours. It was also noted that guidance needs to be given to practitioners on how to document these 500 hours.

Dr. Steinbergh moved to table this rule for further discussion. Mr. Zaayer seconded the motion. All members voted aye. The motion carried.

Ms. Debolt stated that rule 4730-2-06 is being amended to reflect the current language in the law.

Dr. Gingrich moved to approve sending this rule out for interested party comment. Ms. Marchal seconded the motion. All members voted aye. The motion carried.

### **III. *New business***

Dr. Steinbergh announced that this would be Mr. Fry's last meeting and thanked him for his service to the committee. She asked the committee if anyone would object to her nominating Mr. Zaayer as the new Chair of the PAPC. No one objected.

Dr. Steinbergh moved to appoint Mr. Zaayer as the Chair of the PAPC. Ms. Petty seconded the motion. All members voted aye. The motion carried.

The Physician Assistant Policy Committee meeting was adjourned by Mr. Fry at approximately 3:24 p.m. on Tuesday, May 10, 2016.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on May 10, 2016.

---

Robert Zaayer, PA-C, Chair, PAPC